- Home
- COCH vs KPTI Comparison
COCH vs KPTI Comparison
Compare COCH & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | KPTI |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 47.6M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | COCH | KPTI |
|---|---|---|
| Price | $0.71 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.00 | ★ $16.00 |
| AVG Volume (30 Days) | 82.9K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $241,000.00 | ★ $146,067,000.00 |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.11 | 0.57 |
| 52 Week Low | $0.36 | $1.72 |
| 52 Week High | $1.89 | $10.99 |
Technical Indicators
Market Signals| Indicator | COCH | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 26.82 |
| Support Level | $0.63 | N/A |
| Resistance Level | $0.76 | $2.16 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 58.39 | 10.23 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).